Refine by
Biologic Therapeutic Articles & Analysis
26 news found
He has held leadership and senior roles at Novartis, GE Healthcare, Quest Diagnostics, Tethys Bioscience and the US Department of Energy. About Juvena Therapeutics Juvena Therapeutics is a biotech company accelerating the development of regenerative therapeutics by unlocking the therapeutic potential of secreted proteins. ...
BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat tumors with minimal impact on the patient's quality of life compared to other available treatment options, such as radiation, chemotherapy or biological treatment modalities. Neutron Therapeutics, Inc. and the Helsinki University Hospital are collaborating to launch the ...
Secreted proteins are a proven class of biologics with tremendous therapeutic potential, as they regulate tissue repair and regeneration, organ development, and immune response to disease. ...
With this partnership dynamic, pharmaceutical companies and research organizations using SilcsBio’s computer-aided drug design services will be able to tap into Helix BioStructure’s 3-D structures of proteins (or other biological targets). This, in turn, enables pharmaceutical researchers a seamless way to confirm the mechanism and engagement of the target, enabling ...
MOBILion’s separations technology provides higher resolution, faster analysis and simpler workflows to reveal molecules that are most important in characterizing biologic therapeutics, discovering biomarkers, and improving the accuracy of diagnostic tests. ...
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. ...
ByIktos
In life science research, methods like LC and LC-MS are usually used to measure therapeutic biological molecules. In order to make the LC and LC-MS systems fulfill their mission, specific standards and reagents are needed. ...
“We’re delighted to welcome Elaine to our growing team, as we realize our mission of bringing forth the next generation of CRISPR-based diagnostics and therapeutics,” said Trevor Martin, co-founder and Chief Executive Officer of Mammoth Biosciences. ...
Terray Therapeutics, a biotechnology company propelling drug discovery into the information age, today announced the appointments of Feroze (Fez) Ujjainwalla, PhD, as Head of Business, and Adam D. ...
Food and Drug Administration (FDA) and will be regulated as a drug-biologic through a therapeutics biologics license application (BLA). Importantly, DiscGenics announced in August 2019 that the FDA granted Fast Track designation for IDCT as a potential treatment option for chronic low back pain. ...
Ghent, Belgium – November 30, 2021 – Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals, Inc. whereby Confo’s technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs (G protein-coupled receptors) in disease-relevant ...
Laurencin currently serves on the Board of Directors of MiMedx Group, Inc., a public company focused on advanced wound care and therapeutic biologics. Dr. Laurencin is a pioneer in the field of regenerative engineering, and an expert in biomaterials science, stem cell technology and nanotechnology. ...
ByAlkermes
MOBILion Systems, Inc., a pioneer in fast, efficient, high-resolution instrumentation for biomarker discovery, diagnostics and therapeutic development, is collaborating with an international research team to identify alterations in the metabolism of selective glycosphingolipids in specific brain regions that contribute to the early onset and progression of Parkinson’s ...
At Immune Biosolutions, we strongly believe that biologics can transform and save lives. Leveraging our technology platforms, we hack the immune system of chickens to discover and engineer the next generation of immunotherapies. Immune Biosolutions is developing a robust pipeline of innovative combinatory biologics in several therapeutic areas, ...
Proceeds will be used to scale the commercialization of MOBIE® to deliver improved biologic therapeutic characterization to the broader biopharma industry and advance product development for expansion into bioprocessing and multiomic biomarker discovery markets. “We believe MOBILion is uniquely positioned to deliver rich biological ...
” In 2018, MOBILion announced its partnership with Agilent Technologies to integrate their first HRIM system with Agilent’s 6500 line of Q-TOF Mass Spectrometers to provide a tool for pharmaceutical companies to develop safer and more effective biologic therapeutics, and aid academic researchers in discovering novel biomarkers. ...
The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and biological response therapeutics that help expedite the wound healing process at the cellular level, resulting in less time and resources spent on more costly treatments. ...
Alloy Therapeutics, a biotechnology ecosystem company empowering the global scientific community to make better medicines together, today announced the close of a $75 million Series C financing round. ...
The union of both platforms delivers on the promise of eliminating impediments to identifying and characterizing CQAs with the reliability, repeatability and speed required in modern biopharmaceutical organizations developing more complex protein therapeutics. “Combining the fastest, highest resolution, most reproducible therapeutic protein analysis with ...
The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive experience and state-of-the-art capabilities in TIL cell therapy, led by the Biologics Development platform, within the Therapeutics Discovery division. ...